Pharma Giants Boehringer Ingelheim and Eli Lilly Halt Major Investments in Germany
The German pharmaceutical landscape is currently navigating a period of significant strategic recalibration as major industry players re-evaluate their domestic capital expenditure plans. Boehringer Ingelheim, one of Germany’s most prominent family-owned pharmaceutical companies, has recently confirmed a shift in its investment strategy, citing concerns over the evolving regulatory and economic environment. This development, occurring alongside … Read more